Crizotinib Impurity 8 CAS 1233484-06-4
| CAS No. | 1233484-06-4 |
| Molecular Formula | C13H9Cl2FN2O3 |
| Molecular Weight | 331.13 g/mol |
| Category | Pharmacopoeial Impurity Standards / EP Impurities |
| Availability | In Stock |
Chemical Structure
Description
The molecular framework of Crizotinib Impurity 8 (C13H9Cl2FN2O3) is characterized by a nitrogen-containing heterocyclic scaffold, an amide group, a hydroxyl group, an ether linkage, fluorine/chlorine substitution. In reversed-phase chromatography, its retention is governed primarily by the protonation state of its nitrogen-containing groups, which provides a practical basis for HPLC-UV/DAD or LC-MS method development. The aromatic system may exhibit native fluorescence, enabling detection with a fluorescence detector (FLD).
As a process- or degradation-related impurity, Crizotinib Impurity 8 (CAS 1233484-06-4, C13H9Cl2FN2O3) is essential for impurity profiling, related-substances testing, and forced-degradation studies in pharmaceutical development.
This reference standard supports related-substances testing and method development in line with ICH Q3A/Q3B guidance on impurity control, and is suitable for system suitability testing and forced-degradation studies.
CATO manufactures Crizotinib Impurity 8 under ISO 17034:2016 accreditation with dual CNAS and ANAB accreditation. Each batch is characterized by orthogonal methods and supplied with a full Certificate of Analysis (COA), ensuring metrological traceability.
Physical & Chemical Properties
| Molecular Formula | C13H9Cl2FN2O3 |
| Molecular Weight | 331.13 g/mol |
| Appearance | Pale yellow to yellow crystalline powder. (slight halide-like odor, low volatility) |
| Purity | >95% |
| Storage | Store at 2-8°C, protect from light, keep sealed and dry |
| Solubility (reference) | Soluble in DMSO, DMF, methanol |
| Stability | May oxidize slowly on prolonged air exposure; Light-sensitive; avoid direct strong light; Hygroscopic; reseal immediately after opening; Contains ester bond; hydrolyzes under strong alkaline conditions |
| Degree of Unsaturation (DBE) | 9.0 |
| UV Absorption | UV-absorbing |
| Structural Features | Aromatic ring present |
| CAS Registry Year (est.) | 1990 |
| Halogen Content | F/Cl-containing |
| Nitrogen Atoms | 2 |
Related Crizotinib Standards
- Crizotinib Impurity 7 (CAS 877397-70-1)
- Crizotinib Impurity 4 (CAS 877399-50-3)
- Crizotinib Impurity 54 (CAS CATO-C4X-102554)
- Crizotinib Impurity 46 (CAS CATO-C4X-102546)
- Crizotinib impurity 17 (CAS 2322541-37-5)
- Crizotinib Impurity 11 (CAS 1448326-32-6)
- Crizotinib Impurity 62 (CAS CATO-C4X-102562)
- Crizotinib Impurity 56 (CAS CATO-C4X-102556)
Recommended Standards
- Halauxifen (free acid) (CAS 943832-60-8)
- 4-(Benzyloxy)-1-bromo-2-(trifluoromethyl)benzene (CAS 678164-30-2)
- 2-Isopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine (CAS 1256359-31-5)
- 3-Iodo-N-(1,3,4-thiadiazol-2-yl)benzamide (CAS 349442-14-4)
- Osimertinib Impurity 56 (CAS CATO-C4X-204556)
- Oxacillin Impurity 9 (CAS CATO-C4X-23219)
- Ticagrelor Impurity 87 (Mixture of Diastereomers) (CAS CATO-C4X-109387)
- 2-(4-(Benzyloxy)phenoxy)ethan-1-amine hydrochloride (CAS 92646-56-5)
- Vitamin K1 Impurity 10 (CAS 132487-95-7)
- Caffeic acid-<SUP>13</SUP>C<SUB>9</SUB> (CAS 1173097-51-2)
- Methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-5-{[(tert-butoxy)carbonyl]amino}pentanoate (CAS 32393-52-5)
- 3-(4-Bromophenyl)-2-sulfanylidene-1,2,3,4-tetrahydroquinazolin-4-one (CAS 1028-39-3)
- 7-(P-tolyl)thieno[3,2-d]pyrimidin-4-ol (CAS 1019152-04-5)
- Tirzepatide (CAS 2023788-19-2)
Why CATO?
- ISO 17034 accredited reference material producer (CNAS + ANAB dual accreditation)
- 130,000+ catalog items in stock, COA supplied with every batch
- Worldwide shipping with full export documentation (HS code guidance available)
- Technical support: +86 18665070610 / Nicole.chen@cato-chem.com